

SPECIFICATION

Please replace paragraph [0001] with the following amended paragraph:

[0001] This application is a continuation-in-part application of co-pending U.S. Patent Application Serial No. ~~40/798,047~~ 10/798,117 filed on March 11, 2004 entitled “Composition and Method for Treating Inflammations” which, in turn, is a completion application of Provisional Patent Application Serial No. 60/461,534 filed on April 9, 2003, the disclosures of which are hereby incorporated by reference.

Please replace paragraphs [0017] – [0018] with the following amended paragraph:

[0017] The antihistamine can be any of those which are commercially available such as those sold under the name “Zyrtec®” (cetirizine), “Allegra®” (fexodenadine), “Claritin®” (loratadine), ~~and “Clarinx®” (desloratadine), and “Astelin®” (azelastine).~~

[0018] The nasal steroid is, preferably, ~~either azelastine or~~ fluticasone propionate. This propionate is sold commercially under the name “Flonase®.” ~~The azelastine is sold commercially under the name “Astelin®.”~~ Other useful nasal steroids are those sold commercially under various trademarks such as, for example, “Nasonex®” (mometasone furoate monohydrate), “Nasacort AQ®” (triamcinolone ~~acetate~~ acetonide), and “Rhinocort Aqua®” (budesonide), to name a few.